NASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Forecast, Price & News $90.30 -3.34 (-3.57%) (As of 09:32 AM ET) Add Compare Share Share Today's Range$90.30▼$91.9050-Day Range$86.67▼$103.9752-Week Range$64.33▼$134.52Volume1,121 shsAverage Volume452,232 shsMarket Capitalization$5.16 billionP/E RatioN/ADividend YieldN/APrice Target$145.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Ascendis Pharma A/S MarketRank™ ForecastAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside59.3% Upside$145.20 Price TargetShort InterestBearish7.10% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.16Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($9.91) to ($8.31) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.04 out of 5 starsMedical Sector587th out of 975 stocksPharmaceutical Preparations Industry271st out of 455 stocks 3.4 Analyst's Opinion Consensus RatingAscendis Pharma A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $145.20, Ascendis Pharma A/S has a forecasted upside of 59.3% from its current price of $91.13.Amount of Analyst CoverageAscendis Pharma A/S has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted7.10% of the outstanding shares of Ascendis Pharma A/S have been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 15.2, which indicates bearish sentiment.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 10.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ASND. Previous Next 3.4 News and Social Media Coverage News SentimentAscendis Pharma A/S has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Ascendis Pharma A/S this week, compared to 4 articles on an average week.Search Interest4 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($9.91) to ($8.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -8.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -8.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAscendis Pharma A/S has a P/B Ratio of 18.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ascendis Pharma A/S (NASDAQ:ASND) StockAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More ASND Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ASND Stock News HeadlinesOctober 2, 2023 | finance.yahoo.comAscendis Presents TransCon™ PTH Data at the American Thyroid Association Annual MeetingSeptember 30, 2023 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Crosses Above 50 Day Moving Average of $95.16October 3, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 23, 2023 | finance.yahoo.comAscendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone DeficiencySeptember 22, 2023 | finance.yahoo.comHere’s What Caused the Volatility in Ascendis Pharma A/S (ASND)September 15, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND) and Laboratory (LH)September 15, 2023 | finance.yahoo.comAscendis Pharma A/S (ASND) Soars 3.2%: Is Further Upside Left in the Stock?September 15, 2023 | finance.yahoo.comAscendis Pharma Launches SKYTROFA® (lonapegsomatropin) in Germany for the Once-Weekly Treatment of Children and Adolescents with Growth Hormone DeficiencyOctober 3, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 14, 2023 | finance.yahoo.comAscendis Pharma Receives Positive CHMP Opinion for TransCon™ PTH (palopegteriparatide) for Adults with Chronic HypoparathyroidismSeptember 12, 2023 | msn.comAscendis Pharma: Revenue Promise Meets Cash Flow ChallengeSeptember 10, 2023 | finance.yahoo.comAnalysts Are Betting On Ascendis Pharma A/S (NASDAQ:ASND) With A Big Upgrade This WeekSeptember 7, 2023 | markets.businessinsider.comBerenberg Bank Reaffirms Their Buy Rating on Ascendis Pharma (ASND)September 7, 2023 | markets.businessinsider.comBank of America Securities Sticks to Its Buy Rating for Ascendis Pharma (ASND)September 6, 2023 | finance.yahoo.comAscendis Pharma A/S (NASDAQ:ASND) Q2 2023 Earnings Call TranscriptSeptember 6, 2023 | finance.yahoo.comIs Ascendis Pharma A/S (ASND) Too Good to Be True? A Comprehensive Analysis of a Potential ...September 6, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND), Abbott Labs (ABT) and Thermo Fisher (TMO)September 5, 2023 | finance.yahoo.comNew Post Hoc Analysis Showed Substantial Improvement in Observed Estimated Glomerular Filtration Rate (eGFR), in TransCon PTH-Treated Adults with HypoparathyroidismSeptember 5, 2023 | finance.yahoo.comAscendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementSeptember 5, 2023 | finance.yahoo.comAscendis Pharma Reports Second Quarter 2023 Financial ResultsSeptember 5, 2023 | finance.yahoo.comRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding AgreementSeptember 4, 2023 | markets.businessinsider.comHere's what Wall Street expects from Ascendis Pharma (spons ADRs)'s earnings reportAugust 28, 2023 | finance.yahoo.comWall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should KnowAugust 28, 2023 | finance.yahoo.comWall Street Analysts Predict a 41.43% Upside in Ascendis Pharma A/S (ASND): Here's What You Should KnowAugust 24, 2023 | finance.yahoo.comHere’s Why Ascendis Pharma A/S (ASND) Declined in Q2August 24, 2023 | finance.yahoo.comAscendis Pharma A/S Announces Three Upcoming Investor PresentationsAugust 15, 2023 | finance.yahoo.comAscendis Pharma to Report Second Quarter 2023 Financial Results and Provide Business Update on September 5, 2023See More Headlines Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Company Calendar Last Earnings9/05/2023Today10/03/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND CUSIPN/A CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees797Year FoundedN/APrice Target and Rating Average Stock Price Forecast$145.20 High Stock Price Forecast$192.00 Low Stock Price Forecast$113.00 Forecasted Upside/Downside+59.3%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($11.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,450,000.00 Net Margins-500.93% Pretax Margin-500.07% Return on Equity-257.83% Return on Assets-58.01% Debt Debt-to-Equity Ratio7.39 Current Ratio3.52 Quick Ratio2.65 Sales & Book Value Annual Sales$119.17 million Price / Sales43.71 Cash FlowN/A Price / Cash FlowN/A Book Value$4.87 per share Price / Book18.71Miscellaneous Outstanding Shares57,152,000Free Float34,291,000Market Cap$5.21 billion OptionableOptionable Beta0.50 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Jan Moller Mikkelsen (Age 63)Pres, CEO, Member of Exec. Board & Exec. Director Mr. Scott T. Smith (Age 49)CFO, Exec. VP & Member of Exec. Board Ms. Lotte Sonderbjerg (Age 62)Exec. VP, Chief Admin. Officer & Member of the Exec. Board Mr. Michael Wolff Jensen L.L.M. (Age 52)Exec. VP, Chief Legal Officer & Member of the Exec. Board Mr. Peter Rasmussen (Age 54)VP of Fin. & Principal Accounting Officer Mr. Timothy J. LeeSr. Director of Investor RelationsMr. Flemming Steen Jensen (Age 62)Exec. VP of Product Supply & Quality - Endocrinology Rare Diseases Dr. Kennett Sprogoe Ph.D. (Age 44)Exec. VP of Research & Product Devel. Dr. Birgitte Volck M.D. (Age 61)Ph.D., Exec. VP and Head of Clinical Devel. & Medical Affairs - Endocrinology Rare Diseases Dr. Jens Sigurd Okkels Ph.D. (Age 62)Exec. VP of Product Devel. More ExecutivesKey CompetitorsElanco Animal HealthNYSE:ELANIntra-Cellular TherapiesNASDAQ:ITCIApellis PharmaceuticalsNASDAQ:APLSAlkermesNASDAQ:ALKSGrifolsNASDAQ:GRFSView All CompetitorsInstitutional OwnershipBarclays PLCSold 68,294 shares on 9/21/2023Ownership: 0.001%Davidson Kempner Capital Management LPBought 6,000,000 shares on 9/12/2023Ownership: 0.000%Wolverine Trading LLCBought 3,857 shares on 8/23/2023Ownership: 0.007%Affinity Asset Advisors LLCBought 17,760 shares on 8/21/2023Ownership: 0.101%Osaic Holdings Inc.Bought 267 shares on 8/21/2023Ownership: 0.002%View All Institutional Transactions ASND Stock - Frequently Asked Questions Should I buy or sell Ascendis Pharma A/S stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ASND shares. View ASND analyst ratings or view top-rated stocks. What is Ascendis Pharma A/S's stock price forecast for 2023? 10 Wall Street analysts have issued 12 month price objectives for Ascendis Pharma A/S's stock. Their ASND share price forecasts range from $113.00 to $192.00. On average, they anticipate the company's share price to reach $145.20 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price. View analysts price targets for ASND or view top-rated stocks among Wall Street analysts. How have ASND shares performed in 2023? Ascendis Pharma A/S's stock was trading at $122.13 at the start of the year. Since then, ASND shares have decreased by 25.4% and is now trading at $91.13. View the best growth stocks for 2023 here. Are investors shorting Ascendis Pharma A/S? Ascendis Pharma A/S saw a decrease in short interest in September. As of September 15th, there was short interest totaling 4,060,000 shares, a decrease of 10.6% from the August 31st total of 4,540,000 shares. Based on an average daily trading volume, of 267,600 shares, the days-to-cover ratio is currently 15.2 days. View Ascendis Pharma A/S's Short Interest. When is Ascendis Pharma A/S's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our ASND earnings forecast. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Tuesday, September, 5th. The biotechnology company reported ($2.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.68) by $0.33. The biotechnology company earned $51.59 million during the quarter, compared to analyst estimates of $41.73 million. Ascendis Pharma A/S had a negative net margin of 500.93% and a negative trailing twelve-month return on equity of 257.83%. What ETFs hold Ascendis Pharma A/S's stock? ETFs with the largest weight of Ascendis Pharma A/S (NASDAQ:ASND) stock in their portfolio include Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Virtus LifeSci Biotech Products ETF (BBP), BNY Mellon Innovators ETF (BKIV), Global X Guru Index ETF (GURU), Harbor Disruptive Innovation ETF (INNO), Fidelity Disruptive Medicine ETF (FMED) and American CenturyFocused Dynamic Growth ETF (FDG). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA). When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager. What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $91.13. How much money does Ascendis Pharma A/S make? Ascendis Pharma A/S (NASDAQ:ASND) has a market capitalization of $5.21 billion and generates $119.17 million in revenue each year. The biotechnology company earns $-614,450,000.00 in net income (profit) each year or ($11.30) on an earnings per share basis. How many employees does Ascendis Pharma A/S have? The company employs 797 workers across the globe. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The official website for the company is www.ascendispharma.com. The biotechnology company can be reached via phone at (457) 022-2244, via email at ir@ascendispharma.com, or via fax at 45-3694-4010. This page (NASDAQ:ASND) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.